CD47 and neoplasm: Systemic administration of Bifidobacterium can lead to its accumulation in the tumor, converting non-responder mice into responders to anti-CD47 immunotherapy in a stimulator of interferon genes (STING) and interferon-dependent manner, ultimately promoting the efficacy of anti-CD47 immunotherapy [20].